Description
Rosuvastatin, a next-generation HMG-CoA reductase inhibitor, offers potent LDL-C lowering with minimal CYP3A4 interaction and limited extrahepatic penetration. This review highlights its pharmacology, efficacy, safety, and findings from major clinical trials in hypercholesterolemia and cardiovascular prevention, underscoring its role in modern lipid management.